Pasadena Private Wealth’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$215K Hold
429
0.03% 236
2026
Q1
$211K Hold
429
0.03% 210
2025
Q4
$249K Hold
429
0.03% 190
2025
Q3
$208K Buy
+429
New +$200K 0.03% 191
2025
Q2
Sell
-427
Closed -$212K 213
2025
Q1
$212K Hold
427
0.04% 173
2024
Q4
$222K Hold
427
0.05% 135
2024
Q3
$264K Hold
427
0.06% 119
2024
Q2
$236K Hold
427
0.05% 126
2024
Q1
$248K Buy
427
+2
+0.5% +$1.12K 0.06% 122
2023
Q4
$226K Sell
425
-9
-2% -$4.36K 0.06% 133
2023
Q3
$220K Buy
434
+9
+2% +$4.8K 0.07% 83
2023
Q2
$222K Hold
425
0.06% 90
2023
Q1
$245K Hold
425
0.07% 80
2022
Q4
$234K Hold
425
0.07% 82
2022
Q3
$216K Hold
425
0.08% 75
2022
Q2
$231K Sell
425
-3
-0.7% -$1.65K 0.08% 70
2022
Q1
$253K Buy
428
+3
+0.7% +$1.72K 0.08% 75
2021
Q4
$284K Buy
+425
New +$265K 0.09% 78

Other funds holding TMO

Pasadena Private Wealth's TMO Position: Q2 2026 in Review

Pasadena Private Wealth held its Thermo Fisher Scientific (TMO) position steady in Q2 2026 at 429 shares worth $215K. The position accounts for 0.03% of the portfolio, ranked #236.

Pasadena Private Wealth first reported a position in TMO in Q4 2021 and has held it in 18 quarters since. The position peaked at $284K in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Pasadena Private Wealth held 429 shares of Thermo Fisher Scientific worth $215K as of Q2 2026.
  • Pasadena Private Wealth left its Thermo Fisher Scientific share count unchanged in Q2 2026.
  • Thermo Fisher Scientific made up 0.03% of Pasadena Private Wealth's portfolio in Q2 2026, its #236 holding.
  • Pasadena Private Wealth first reported a position in Thermo Fisher Scientific in Q4 2021 and has held it in 18 quarters since.
  • Pasadena Private Wealth's Thermo Fisher Scientific position peaked at $284K in Q4 2021.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Pasadena Private Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.